Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
B Hallberg, RH Palmer - Nature Reviews Cancer, 2013 - nature.com
The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many
cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer …
cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer …
OF THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS OF THE HEMATOPOIETIC AND LYMPHOID TISSUES
This manuscript represents a review of lymphoblastic leukemia/lymphoma (acute
lymphoblastic leukemia/lymphoblastic lymphoma), acute leukemias of ambiguous lineage …
lymphoblastic leukemia/lymphoblastic lymphoma), acute leukemias of ambiguous lineage …
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
ER Parrilla Castellar, ES Jaffe, JW Said… - Blood, The Journal …, 2014 - ashpublications.org
Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a
CD30-positive T-cell non-Hodgkin lymphoma that morphologically resembles ALK-positive …
CD30-positive T-cell non-Hodgkin lymphoma that morphologically resembles ALK-positive …
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes
International T-Cell Lymphoma Project - Journal of clinical oncology, 2008 - ascopubs.org
Purpose Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are
rare and heterogeneous forms of non-Hodgkin's lymphoma (NHL) that, in general, are …
rare and heterogeneous forms of non-Hodgkin's lymphoma (NHL) that, in general, are …
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype
Background Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent
nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations …
nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations …
[图书][B] Pathology and genetics of tumours of haematopoietic and lymphoid tissues
ES Jaffe - 2001 - books.google.com
This is the third volume in the new World Health Organization series on histological and
genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered …
genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered …
ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified …
Abstract The International Peripheral T-Cell Lymphoma Project is a collaborative effort
designed to gain better understanding of peripheral T-cell and natural killer (NK)/T-cell …
designed to gain better understanding of peripheral T-cell and natural killer (NK)/T-cell …
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
H Stein, HD Foss, H Dürkop… - Blood, The Journal …, 2000 - ashpublications.org
Anaplastic large cell lymphoma (ALCL) represents a generally recognized group of large
cell lymphomas. Defining features consist of a proliferation of predominantly large lymphoid …
cell lymphomas. Defining features consist of a proliferation of predominantly large lymphoid …
The biology and management of systemic anaplastic large cell lymphoma
G Hapgood, KJ Savage - Blood, The Journal of the American …, 2015 - ashpublications.org
Systemic anaplastic large cell lymphoma (ALCL) is an aggressive CD30+ non-Hodgkin
lymphoma. Anaplastic lymphoma kinase–positive (ALK+) ALCL is associated with the NPM …
lymphoma. Anaplastic lymphoma kinase–positive (ALK+) ALCL is associated with the NPM …
Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 …
MW Bekkenk, FAMJ Geelen, PCV Vader… - Blood, The Journal …, 2000 - ashpublications.org
To evaluate our diagnostic and therapeutic guidelines, clinical and long-term follow-up data
of 219 patients with primary or secondary cutaneous CD30+ lymphoproliferative disorders …
of 219 patients with primary or secondary cutaneous CD30+ lymphoproliferative disorders …